VRNA Earnings Prediction
The chart below shows how VRNA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VRNA sees a -1.58% change in stock price 10 days leading up to the earnings, and a -3.89% change 10 days following the report. On the earnings day itself, the stock moves by +1.37%. This data can give you a slight idea of what to expect for the next quarter's release.
VRNA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
28.61M
--
561.45%
Gross Margin
94.44%
--
4.54%
Operating Margin
-50.03%
--
-93.08%
Net Margin
-92.28%
--
-87.92%
EPS
-0.04
-100.00%
-20.00%
No Data Available
VRNA Earnings Analysis
Verona Pharma PLC Corporation (VRNA.O) Earnings Conference Call
Positive
FDA Approval and Launch: 2024 was a transformational year for Verona Pharma with the U.S. FDA approval and commercial launch of Ohtuvayre for the maintenance treatment of COPD.
Strong Sales Momentum: Net sales of Ohtuvayre were $36.6 million in Q4 2024 and $42.3 million for the full year 2024, indicating strong initial launch momentum.
Prescription Dispensing Growth: More prescriptions were dispensed in the first two months of Q1 2025 than in Q4 2024, showing continued growth.
Strong Prescriber Base: Over 4,600 unique healthcare providers (HCPs) are prescribing Ohtuvayre, including 55% of Tier 1 HCPs, demonstrating a strong prescriber base.
Physician Confidence in Ohtuvayre: 275 HCPs have prescribed Ohtuvayre to more than 20 patients, indicating confidence in the product.
Broad COPD Treatment Approach: Ohtuvayre is being prescribed across a broad range of COPD patients, including those on various therapy backgrounds, which supports its novel treatment approach.
Patient and HCP Feedback: Positive feedback from patients and HCPs about Ohtuvayre's impact is encouraging, supported by refill and persistency data.
Clinical Trial Success: The company successfully completed a Phase 2 dose-ranging clinical trial with glycopyrrolate, paving the way for further clinical development.
Global Product Approval Expansion: Nuance Pharma announced the approval of Ohtuvayre in Macau, marking the first approval outside the U.S., expanding the product's global reach.
Phase 2 Trial Progress: Enrollment continues in the Phase 2 trial for nebulized ensifentrine in bronchiectasis, indicating ongoing pipeline development.
Negative
Increased Net Loss: Net loss after tax increased significantly to $33.8 million in Q4 2024, compared to $14.1 million in Q4 2023, indicating worsening financial performance.
Annual Net Loss Increase: Total net loss for the year reached $173.4 million, up from $54.4 million in 2023, highlighting a concerning trend in annual losses.
R&D Cost Surge: Research and development costs surged to $7.9 million in Q4 2024, up from $4.1 million in Q4 2023, reflecting increased spending without immediate returns.
Rising Operational Costs: Selling, general, and administrative expenses rose dramatically to $45.1 million in Q4 2024, compared to $15 million in Q4 2023, indicating high operational costs associated with the product launch.
Earnings Per Share Decline: The company reported a loss of $0.05 per ordinary share for Q4 2024, compared to a loss of $0.02 per ordinary share in Q4 2023, showing deteriorating earnings per share.
Financial Health Concerns: Despite the launch of Ohtuvayre, the overall financial health is concerning due to the high operational costs and increasing losses.
VRNA FAQs
How does VRNA typically perform around its earnings report dates?
Is Verona Pharma PLC (VRNA) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VRNA Earning Call Sentiment
Verona Pharma plc (VRNA) Q4 2024 Earnings Call Transcript
VRNA.O
-6.07%Positive
The earnings call shows strong sales growth for Ohtuvayre and optimism about future revenue, despite increased expenses. Management's refusal to provide specific guidance and the lack of clear answers on potential headwinds slightly dampen sentiment. However, the positive outlook, stable cash position, and potential breakeven point by 2025 contribute positively. The company's small-cap status suggests a more pronounced reaction, leading to a positive stock price movement prediction.
